Advanced search
Publication Cover
Emerging Microbes & Infections Volume 11, 2022 - Issue 1
Submit an article Journal homepage
3,951
Views
9
CrossRef citations to date
0
Altmetric
Coronaviruses

mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern

Haomeng Wanga CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of China;c CanSino Biologics, Tianjin, People’s Republic of China;d CanSino (Shanghai) Biological Research Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Zhao Chenb State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaView further author information
,
Zhenghua Wanga CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of China;c CanSino Biologics, Tianjin, People’s Republic of China;d CanSino (Shanghai) Biological Research Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Jin Lia CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of China;c CanSino Biologics, Tianjin, People’s Republic of China;d CanSino (Shanghai) Biological Research Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Zhihong Yana CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of China;c CanSino Biologics, Tianjin, People’s Republic of China;d CanSino (Shanghai) Biological Research Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Jinbo Yuana CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of China;c CanSino Biologics, Tianjin, People’s Republic of China;d CanSino (Shanghai) Biological Research Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Airu Zhub State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaView further author information
,
Lan Chenb State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaView further author information
,
Ye Liua CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of China;c CanSino Biologics, Tianjin, People’s Republic of China;d CanSino (Shanghai) Biological Research Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Chenlong Hua CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of China;c CanSino Biologics, Tianjin, People’s Republic of China;d CanSino (Shanghai) Biological Research Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Ali Zhua CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Guowei Lia CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of China;c CanSino Biologics, Tianjin, People’s Republic of China;d CanSino (Shanghai) Biological Research Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Yuehu Lia CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of China;c CanSino Biologics, Tianjin, People’s Republic of China;d CanSino (Shanghai) Biological Research Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Jie Dengc CanSino Biologics, Tianjin, People’s Republic of ChinaView further author information
,
Liqiao Mac CanSino Biologics, Tianjin, People’s Republic of ChinaView further author information
,
Xiuwen Suic CanSino Biologics, Tianjin, People’s Republic of ChinaView further author information
,
Wei Miaoc CanSino Biologics, Tianjin, People’s Republic of ChinaView further author information
,
Junqiang Lic CanSino Biologics, Tianjin, People’s Republic of ChinaView further author information
,
Xiuyu Zhengc CanSino Biologics, Tianjin, People’s Republic of ChinaView further author information
,
Jinhua Piaoc CanSino Biologics, Tianjin, People’s Republic of ChinaView further author information
,
Yanfeng Yaoh Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People’s Republic of ChinaView further author information
,
Juhong Raoi State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People’s Republic of ChinaView further author information
,
Chao Shani State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People’s Republic of China;j Hubei Jiangxia Laboratory, Wuhan, People’s Republic of ChinaView further author information
,
Zhiming Yuanh Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-3234-9616View further author information
ORCID Icon,
Jincun Zhaob State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China;e Institute of Infectious Disease, Guangzhou Eighth People’s Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China;f Guangzhou Laboratory, Bio-Island, Guangzhou, People’s Republic of China;g Shanghai Institute for Advanced Immunochemical Studies, School of Life Science and Technology, ShanghaiTech University, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
View further author information
&
Tao Zhua CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of China;c CanSino Biologics, Tianjin, People’s Republic of China;d CanSino (Shanghai) Biological Research Co., Ltd, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
View further author information
 show all
Pages 1550-1553 | Received 01 Mar 2022, Accepted 19 May 2022, Published online: 04 Jun 2022

References

  • van de Veerdonk FL, Gsiamarellos-Bourboulis E, Pickkers P, et al. A guide to immunotherapy for COVID-19. Nat Med. 2022;28:39–50.
  • Ndwandwe D, Wiysonge CS. COVID-19 vaccines. Curr Opin Immunol. 2021;71:111–116.
  • Hogan MJ, Pardi N. mRNA vaccines in the COVID-19 pandemic and beyond. Annu Rev Med. 2022;73(1):17–39.
  • Pilkington EH, Suys E JA, Trevaskis NL, et al. From influenza to COVID-19: lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases. Acta Biomater. 2021;131(1):16–40.
  • Qu L, Yi ZY, Shen Y, et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell. 2022;185(10):1728–1744.
  • Zhang NN, Zhang RR, Zhang YF, et al. Rapid development of an updated mRNA vaccine against the SARS-CoV-2 Omicron variant. Cell Res. 2022;32(4):401–403.
  • Yan W, Zheng Y, Zeng X, et al. Structural biology of SARS-CoV-2: open the door for novel therapies. Sig Transduct Target Ther. 2022;7(1):26.
  • Pegu A, O’Connell SE, Schmidt SD. Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants. Science; 2021;373:1372–1377.
  • Sievers BL, Chakraborty S, Xue Y, et al. Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses. Sci. Transl. Med. 2022. doi:10.1126/scitranslmed.abn7842.
  • Cai C, Liu Y, Zeng S. The efficacy of COVID-19 vaccines against the B.1.617.2 (delta) variant. Mol Ther. 2021;29(10):289–2892.
  • Wang Y, Ma Y, Xu Y, et al. Resistance of SARS-CoV-2 Omicron variant to convalescent and CoronaVac vaccine plasma. Emerg Microbes Infect. 2022;11(1):424–427.
  • Kennedy RB. Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine. Lancet. 2022;399:212–213.
  • Ying B, Scheaffer SM, Whitener B, et al. Boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibody responses and protection against B.1.1.529 infection in mice. Preprint. bioRxiv. 2022.02.07.479419. doi:10.1101/2022.02.07.479419.
  • Lee IJ, Sun CP, Wu PY, et al. Omicron-specific mRNA vaccine induced potent neutralizing antibody against Omicron but not other SARS-CoV-2 variants. bioRxiv. 2022.01.31.478406. doi:10.1101/2022.01.31.478406.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.